Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 50 for your search:
Drug:
gp100 antigen
Find trials that include:
Any drugs shown
Trial Status:
Closed
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Sargramostim (GM-CSF) and Peptide Vaccination Comprising Tyrosinase:368-376, gp100:209-217 (210M) Antigen, and MART-1:27-35 Peptide Versus Peptide Vaccination Alone Versus GM-CSF Alone Versus Placebo in Patients With Locally Advanced or Metastatic Melanoma
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ECOG-4697
, SWOG-E4697, E4697, NCT00005034
2.
Phase III Randomized Study of Adjuvant NA17-A and Melanoma Differentiation Peptides in HLA-A2-Positive Patients With Primary Ocular Melanoma at High Risk of Relapse
Phase:
Phase III
Type:
Treatment
Status:
Closed
Age:
Over 18
Sponsor:
Other
Protocol IDs:
EORTC-18001
, EORTC-88001, NCT00036816
3.
Phase I/II Study of Immunization With Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigens MART-1 and gp100 With or Without Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-97-C-0046
, NCI-97-C-0019, NCI-T96-0046N, T96-0046, NCT00019214
4.
Phase I/II Randomized Study of Antigen-Pulsed Autologous Dendritic Cells for Induction of Antitumor Immunity in Patients Completing Lymphadenectomy for Metastatic Melanoma (Summary Last Modified 05/2000)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Completed
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
DUMC-719975
, DUMC-0932-99-5R2, DUMC-759-99-5R2, UVA-HIC-7454, NCI-G98-1398, NCT00003229
5.
Phase I/II Study of Ad2/MART-1v2 and Ad2/gp100v2 Melanoma Antigen Vaccines in Patients With Stage II, III, or IV Melanoma (Summary Last Modified 07/2002)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GENZ-ADVMEL-001-99
, DFCI-00069, GENZ-2000-P-000380/1, NCT00010309
6.
Phase I/II Pilot Study of a Multi-Epitope Peptide Vaccine With Sargramostim (GM-CSF) Plasmid DNA Immune Adjuvant in Patients With Stage IIB, IIC, III, or IV Melanoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Closed
Age:
Any age (weight > 25 kg)
Sponsor:
NCI
Protocol IDs:
MSKCC-00142A
, 5906, NCI-5906, NCT00085137
7.
Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0023
, NCI-T97-0089, T97-0089
8.
Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0040
, NCI-T97-0092, T97-0092, NCT00019396
9.
Phase II Study of Vaccination with Synthetic Melanoma Peptide Administered with Sargramostin (GM-CSF) Plus Interleukin-2 in Patients with Advanced Melanoma (Summary Last Modified 04/2002)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18-79
Sponsor:
NCI
Protocol IDs:
UVACC-HIC-7621
, UVA-HIC-7621, NCI-G98-1389, NCT00003222
10.
Phase II Randomized Study of Vaccine Comprising Tyrosinase Peptide and gp100 Antigen With Montanide ISA-51 Alone or With Sargramostim (GM-CSF) in Patients with Resectable Stage IIA or IIB Melanoma (Summary Last Modified 11/2001)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M971
, LAC-USC-FDR001101, NCI-T97-0100, NCT00003274, T97-0100
11.
Phase II Study of DNA Encoding the gp100 Antigen Alone or in Combination With Interleukin-2 in Patients With Recurrent Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0086
, NCI-T97-0121, T97-0121, NCT00019448
12.
Phase II Randomized Study of a Vaccine Combining Tyrosinase and gp100 Peptides Emulsified with Montanide ISA-51 With or Without Interleukin-12 for Patients with Resected Stage III or IV Melanoma (Summary Last Modified 03/2000)
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M973
, NCI-G98-1432, NCI-T97-0099, NCT00003339, T97-0099
13.
Phase II Randomized Study of gp100-Tyrosinase Peptide Vaccine Using Sargramostim (GM-CSF), Montanide ISA-51, or QS21 as Adjuvant in Patients with Advanced Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-98012
, NCI-T97-0110, NCT00003362, T97-0110
14.
Phase II Study of Immunization With gp100 Antigen With Endoplasmic Reticulum Insertion Signal Sequence Alone or in Combination With Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-98-C-0142
, NCI-T98-0036, T98-0036
15.
Phase II Randomized Study of Mutated gp100 Melanoma Peptide With High-Dose Interleukin-2 in HLA-A2.1-Positive Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
CWG-UIC-T98-0027
, NCI-T98-0027, NCT00003568, T98-0027
16.
Phase II Study of Recombinant Fowlpox Virus Encoding gp100 Peptide Preceded By an Endoplasmic Reticulum Insertion Signal in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0044
, NCI-T98-0088, T99-0088, NCT00019669
17.
Phase II Study of MART-1 and gp100 Peptides Modified to Increase Binding to HLA-A0201 With or Without Interleukin-2 in Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0092
, NCI-T99-0033, T99-0033, NCT00019721
18.
Phase II Randomized Study of Mutated gp100 Melanoma Vaccine in HLA-A2-Positive Patients With at Least 1 mm Melanoma on Initial Biopsy
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
Over 16
Sponsor:
NCI
Protocol IDs:
PPMC-IRB-99-9
, NCI-T98-0081, NCT00003895, T98-0081
19.
Phase II Study of Immunization Using gp100:44-59, gp100:209-217 (210M), and MART-1:26-35 (27L) Antigen Peptides in HLA-DRB1*0401 Positive Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-99-C-0159
, NCI-T99-0079, T99-0079, NCT00019994
20.
Phase II Study of gp100 Human Melanoma Peptide Vaccine and Interleukin-2 in Patients With Advanced Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CLB-509901
, NCT00005949, CALGB-509901
21.
Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Closed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M991
, NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102
22.
Phase II Randomized Study of Immunization With an HLA-A2 Multiepitope Peptide Vaccine Comprising MART-1:27-35, gp100:209-217 (210M), and Tyrosinase:368-376 (370D) Peptides Alone or in Combination With Sargramostim (GM-CSF) and/or Interferon alfa-2b in HLA-A2 Positive Patients With Metastatic Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
E-1696
, NCT00006385, E1696
23.
Phase II Randomized Study of gp100:209-217 (210M) or gp100:17-25 Antigen and Tyrosinase:368-376 (370D), Tyrosinase:240-251 (244S), Tyrosinase:206-214, or Tyrosinase-Related Protein-1 (ORF3):1-9 Peptide Emulsified in Montanide ISA-51 in Patients With Melanoma at High Risk for Recurrence
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-00-C-0216
, NCI-2391, 2391, NCT00020358
24.
Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
NCI-01-C-0074
, NCI-2910, 2910, NCT00020475
25.
Phase II Randomized Adjuvant Study of Vaccination With Tyrosinase, gp100, and MART-1 Peptides Emulsified With Montanide ISA-51 With Interleukin-12 and Either Alum Adjuvant or Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma
Phase:
Phase II
Type:
Treatment
Status:
Completed
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
LAC-USC-10M011
, LAC-USC-IRB-013030, NCI-5506, NCT00031733, 5506
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
